Fig. 2From: Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trialPercentage reduction in whole brain volume from baseline, and from Week 24 (inset). ITT population dosed in Year 2. *p < 0.05; † p < 0.01; ‡ p < 0.001 vs delayed treatment (Wilcoxon rank-sum test)Back to article page